Insilico Medicine and China Medical System Holdings (CMS) have announced a new AI-empowered drug discovery collaboration targeting a mass-market central nervous system (CNS) indication, deepening a partnership that was first unveiled three months ago.
The agreement centres on a novel mechanism of action identified using PandaOmics, Insilico's target discovery engine, which is part of the company's broader Pharma.ai suite, alongside its Chemistry42 molecule-generation platform and inClinico trial-outcome prediction tool.
Under the deal, Insilico is eligible to receive up to approximately RMB 1.2bn in milestone payments plus royalties.
The two companies will jointly progress the programme, combining Insilico's generative AI drug discovery capabilities with CMS's clinical development infrastructure, regulatory expertise and commercial reach across China.
CMS, a Hong Kong- and Singapore-listed company, has built its business model around linking innovation with commercialisation and lifecycle management for pharmaceutical products.
Lam Kong, Chair, CEO, President and Executive Director of CMS, said the company was "deeply impressed" by Insilico's productivity in AI drug discovery, describing the two firms' capabilities as "strategically complementary" across discovery, clinical translation and commercialisation.
In addition, CMS has built solid strengths in clinical development systems and efficiency, regulatory submission expertise and commercialisation network coverage.
Dr Feng Ren, Co-CEO and Chief Scientific Officer of Insilico Medicine, said the speed of the follow-on deal reflected a "seamless and productive" first collaboration.
In this new programme, we value the input from the CMS commercialisation team and are proud of the innovative MoA identified by PandaOmics, which streamlines the development of high-potential drugs, enhancing translational efficiency and accelerating the transition of molecules from 'proof of concept' to life-changing patient therapies.
"We will continue to deepen our multi-dimensional collaboration in pipeline and clinical strategy and global partnerships to provide patients with more differentiated and accessible treatment options."
The tie-up adds to a growing list of partnerships for Insilico, which has separately worked with Eli Lilly, Hisun Pharma, Servier, Qilu Pharmaceutical and Fosun Pharma, among others.
The company has also been advancing ISM8969, a brain-penetrant NLRP3 inhibitor for CNS disorders, through a separate co-development deal with Hygtia Therapeutics.
The latest agreement highlights the growing role of generative AI platforms in target identification for complex, high-prevalence indications, as pharma companies increasingly look to shorten the path from target discovery to clinical proof of concept.
